Gamifant approved in China for the treatment of primary haemophagocytic lymphohistiocytosis
Sobi® today announced that the National Medical Products Administration of China (NMPA) has approved Gamifant® (emapalumab) for use in China. The indication is for treatment of adult and paediatric (newborn and older) patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy. The approval followed the recommendation announced in February 2022. Primary HLH is an ultra-rare, life-threatening, hyperinflammatory disorder, characterised by uncontrolled activation of the immune system. Morbidity